Details of the Drug Combinations

General Information of This Drug (ID: DMOB58Q)

Drug Name

MK-8228 DMOB58Q

Synonyms

Letermovir

Indication

Disease Entry	ICD 11	Status	REF
Cytomegalovirus Disease	1D82	Approved	[1]
Cytomegalovirus infection	1D82	Phase 3	[2]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
MK-8228 + MK-8228	DCH0QWY	MK-8228	HIV Infections	[3]
------------------------------------------------------------------------------------

References

1	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
2	The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol. 2011 Oct;85(20):10884-93.
3	ClinicalTrials.gov (NCT04840199) A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes.